文章：

IER3：探索其作为癌基因和抑癌基因的双重功能

IER3: exploring its dual function as an oncogene and tumor suppressor

原文发布日期：2025-03-16 

英文摘要：

The IER3 gene has a complex role in cancer biology, acting either as a tumor suppressor or an oncogene, depending on the cancer type. This duality underscores the complexity and importance of molecular pathways in modulating cancer behavior. Despite its significance in cancer development, there is a dearth of studies elucidating the exact mechanisms underlying IER3’s involvement in modulating cancer behavior. Here, utilizing cervical carcinoma and neuroblastoma (NB) cell lines as model systems we characterized the pathways that mediate the functional switch between the oncogenic and tumor suppressor roles of IER3. In HeLa cells, IER3 expression promotes an oncogenic program that includes immediate early response pathway genes such as EGR2, FOS, and JUN. However, in NB cells, IER3 suppresses the EGR2-dependent oncogenic program. This differential regulation of EGR2 by IER3 involves epigenetic modulation of the EGR2 promoter. IER3 dependent tumor suppressor pathway in NB cells relies on ADAM19 gene. Thus, our findings uncover the molecular pathways that dictate the context-dependent roles of IER3 in cancer, providing insights into its dual functionality in different cancer types. 

摘要翻译：

IER3基因在癌症生物学中扮演着复杂角色，其既可充当肿瘤抑制因子也可作为癌基因，具体功能取决于癌症类型。这种双重性揭示了分子通路在调控癌症行为中的复杂性与重要性。尽管IER3在癌症发展中具有重要意义，但目前缺乏阐明其参与调控癌症行为确切机制的研究。本研究以宫颈癌和神经母细胞瘤（NB）细胞系为模型系统，揭示了介导IER3在致癌与抑癌角色间功能转换的通路机制。在HeLa细胞中，IER3表达会促进致癌程序，包括激活早期即时反应通路基因（如EGR2、FOS和JUN）。然而在NB细胞中，IER3会抑制EGR2依赖的致癌程序。IER3对EGR2的这种差异调控涉及EGR2启动子的表观遗传修饰。NB细胞中IER3依赖的肿瘤抑制通路则依赖于ADAM19基因。因此，我们的研究结果揭示了决定IER3在癌症中上下文依赖性功能的分子通路，为理解其在不同癌症类型中的双重功能提供了新见解。

原文链接：

IER3: exploring its dual function as an oncogene and tumor suppressor